Xponance Inc. Buys 91,843 Shares of Pfizer Inc. (NYSE:PFE)

Xponance Inc. lifted its stake in Pfizer Inc. (NYSE:PFE) by 11.5% during the fourth quarter, HoldingsChannel reports. The firm owned 891,024 shares of the biopharmaceutical company’s stock after purchasing an additional 91,843 shares during the period. Xponance Inc.’s holdings in Pfizer were worth $25,653,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Worth Asset Management LLC purchased a new stake in Pfizer in the first quarter worth about $29,000. Briaud Financial Planning Inc purchased a new stake in Pfizer in the third quarter worth about $30,000. GoalVest Advisory LLC lifted its stake in Pfizer by 304.9% in the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 811 shares during the period. Mizuho Securities Co. Ltd. purchased a new stake in Pfizer in the third quarter worth about $34,000. Finally, VisionPoint Advisory Group LLC lifted its stake in Pfizer by 52,350.0% in the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 1,047 shares during the period. 68.36% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on PFE. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research note on Monday. Guggenheim began coverage on shares of Pfizer in a research report on Friday, February 23rd. They set a “buy” rating and a $36.00 price target for the company. TD Cowen lowered shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target for the company. in a research report on Thursday, January 4th. Finally, Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Twelve research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, Pfizer currently has a consensus rating of “Hold” and an average target price of $36.88.

Pfizer Stock Performance

NYSE:PFE traded down $0.03 during midday trading on Thursday, hitting $25.39. The company’s stock had a trading volume of 35,472,911 shares, compared to its average volume of 42,406,477. Pfizer Inc. has a fifty-two week low of $25.23 and a fifty-two week high of $40.56. The firm’s 50 day moving average is $27.19 and its 200-day moving average is $28.76. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69. The firm has a market cap of $143.77 billion, a P/E ratio of 70.25, a P/E/G ratio of 1.16 and a beta of 0.61.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.29. The business had revenue of $14.25 billion for the quarter, compared to analysts’ expectations of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The business’s revenue was down 41.3% on a year-over-year basis. During the same quarter last year, the company earned $1.14 EPS. Equities analysts anticipate that Pfizer Inc. will post 2.24 earnings per share for the current fiscal year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.